I Interested In Nor Cal Kaiser Patients Offered BCG/Anktive Treatment, Post FDA Approval, For Hi Grade Non Muscle Invasive Cancer.
Generally this seems to be much more effective for folks who are BCG non responsive within 6 months (or a year?) of induction. It was approved by the FDA in April 24.
Yes, the FDA approved the immunotherapy drug nadofaragene firadenovec (Anktiva) in April 2022 for treating BCG-unresponsive non-muscle invasive bladder cancer. Studies found it improved outcomes… read more
Does Anyone Know The Status Of The BCG Shortage In Jan 2025?
The new manufacturing plant was/is scheduled to come online this year and hopefully will eliminate the shortage that has been causing split dosages (mine is spilt 1/3 in maintenance—induction for me was full doses.)
Unfortunately there is no clear information on the status of the BCG shortage in January 2025. However, a new manufacturing plant was scheduled to open in 2024 which hopefully helped address the… read more